<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807586</url>
  </required_header>
  <id_info>
    <org_study_id>ep002</org_study_id>
    <nct_id>NCT00807586</nct_id>
  </id_info>
  <brief_title>Corticosteroid Pulse After Ablation</brief_title>
  <acronym>SAAB</acronym>
  <official_title>SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Heart Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Heart Institute Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiofrequency ablation is an effective treatment for atrial fibrillation. However, about 20%
      of the time the atrial fibrillation recurs. Steroids given after the ablation may decrease
      inflammation caused by the ablation and thus improve healing and decrease the chance of
      recurrence of atrial fibrillation.

      In this study patients will be randomized to receive intravenous steroids or not immediately
      following the ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation, a common arrhythmia, is the source of considerable morbidity. Prevalence
      of atrial fibrillation in adults is 0.5%, increasing to 10% in those patients over the age of
      seventy five. Numbers are expected to increase nearly 2.5 fold over the next 50 years.
      Radiofrequency (RF) ablation to cure atrial fibrillation has become an established and
      effective therapy in the many atrial fibrillation patients. However, approximately 20% return
      with recurrent atrial fibrillation after ablation.

      RF ablation directly targets the substrate for atrial fibrillation, cauterizing cardiac
      tissue through the application of radiofrequency energy , causing a myocardial lesion which
      effectively blocks the errant pathway. This process of RF ablation induces an inflammatory
      effect. As the lesion heals it often enlarges. This may contribute to recurrence of atrial
      fibrillation after ablation, as well as increased pain. There is some early evidence that a
      single dose of corticosteroids after ablation may improve the healing process, thus
      decreasing pain and incidence of recurrent atrial fibrillation.

      The aim of the study is to determine the usefulness of a one time dose of solumedrol
      following radiofrequency ablation for atrial fibrillation..
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinically significant atrial arrhythmias include ER, urgent care, or hospitalization for atrial fibrillation, cardioversion for atrial fibrillation, or atrial fibrillation requiring an increase in anti-arrhythmia medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Pain Assessment</measure>
    <time_frame>one day and one week</time_frame>
    <description>Perception of cardiac pain assessed by a numerical pain scale (0= no pain; 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms Post Ablation Requiring Diuretic</measure>
    <time_frame>6 weeks</time_frame>
    <description>Occurrence of shortness of breath or edema requiring administration of a diuretic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat Intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Need for repeat ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solumedrol</intervention_name>
    <description>100mg, given once within 2 hours of the end of the ablation procedure</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline (1.6 cc)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18

          -  Drug refractory, symptomatic paroxysmal atrial fibrillation

        Exclusion Criteria:

          -  Contraindication to solumedrol

          -  Persistent or permanent Atrial Fibrillation

          -  Previous history of radiofrequency ablation for atrial fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P Melby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grubb NR, Furniss S. Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation. BMJ. 2001 Mar 31;322(7289):777-80. Review.</citation>
    <PMID>11282867</PMID>
  </reference>
  <reference>
    <citation>Pappone C, Santinelli V. Atrial fibrillation ablation: state of the art. Am J Cardiol. 2005 Dec 19;96(12A):59L-64L. Epub 2005 Oct 5. Review.</citation>
    <PMID>16399094</PMID>
  </reference>
  <reference>
    <citation>Fenelon G, Franco M, Mora O, Katchburian E, de Paola AA. Combined therapy with steroids and antioxidants prevents ultrastructural damage surrounding chronic radiofrequency lesions. Pacing Clin Electrophysiol. 2004 Jan;27(1):65-72.</citation>
    <PMID>14720157</PMID>
  </reference>
  <reference>
    <citation>Fenelon G, Fernandes R, Franco M, de Paola AA. Steroids prevent late extension of radiofrequency lesions in the thigh muscle of infant rats: implications for pediatric ablation. J Interv Card Electrophysiol. 2003 Aug;9(1):7-13.</citation>
    <PMID>12975564</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2008</study_first_posted>
  <results_first_submitted>December 3, 2013</results_first_submitted>
  <results_first_submitted_qc>July 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Radiofrequency catheter ablation for atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Steroid</title>
          <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Normal saline (1.6 cc)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Steroid</title>
          <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Normal saline (1.6 cc)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="10.2"/>
                    <measurement group_id="B2" value="60.0" spread="11.4"/>
                    <measurement group_id="B3" value="60.1" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks</title>
        <description>Clinically significant atrial arrhythmias include ER, urgent care, or hospitalization for atrial fibrillation, cardioversion for atrial fibrillation, or atrial fibrillation requiring an increase in anti-arrhythmia medication</description>
        <time_frame>6 weeks</time_frame>
        <population>3 patients lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline (1.6 cc)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks</title>
          <description>Clinically significant atrial arrhythmias include ER, urgent care, or hospitalization for atrial fibrillation, cardioversion for atrial fibrillation, or atrial fibrillation requiring an increase in anti-arrhythmia medication</description>
          <population>3 patients lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Pain Assessment</title>
        <description>Perception of cardiac pain assessed by a numerical pain scale (0= no pain; 10=worst pain imaginable)</description>
        <time_frame>one day and one week</time_frame>
        <population>4 patients lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline (1.6 cc)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Pain Assessment</title>
          <description>Perception of cardiac pain assessed by a numerical pain scale (0= no pain; 10=worst pain imaginable)</description>
          <population>4 patients lost to follow up</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Scale Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.5"/>
                    <measurement group_id="O2" value="1.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Scale Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.9"/>
                    <measurement group_id="O2" value="0.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms Post Ablation Requiring Diuretic</title>
        <description>Occurrence of shortness of breath or edema requiring administration of a diuretic</description>
        <time_frame>6 weeks</time_frame>
        <population>Data were not collected on this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline (1.6 cc)</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms Post Ablation Requiring Diuretic</title>
          <description>Occurrence of shortness of breath or edema requiring administration of a diuretic</description>
          <population>Data were not collected on this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Repeat Intervention</title>
        <description>Need for repeat ablation</description>
        <time_frame>3 months</time_frame>
        <population>14 patients lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline (1.6 cc)</description>
          </group>
        </group_list>
        <measure>
          <title>Repeat Intervention</title>
          <description>Need for repeat ablation</description>
          <population>14 patients lost to follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>there were Adverse Events collected from six weeks to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Steroid</title>
          <description>Solumedrol: 100mg, given once within 2 hours of the end of the ablation procedure</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Normal saline (1.6 cc)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Edema/fluid overload</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a single center study trial</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Melby</name_or_title>
      <organization>Minneapolis Heart Institute Foundation</organization>
      <phone>612-863-3900</phone>
      <email>daniel.melby@allina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

